CytomX Therapeutics Stock News

Metropolitan Life Insurance Co NY lifted its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 118,175.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,924 shares of the biotechnology companys stock after purchasing an additional 18,908 shares during []

California State Teachers Retirement System trimmed its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 3.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,596 shares of the biotechnology companys stock after selling 3,310 shares during the period. []

Investors need to pay close attention to CytomX Therapeutic (CTMX) stock based on the movements in the options market lately.

Equities researchers at BTIG Research assumed coverage on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research note issued to investors on Monday, Price Targets.com reports. The brokerage set a buy rating and a $16.00 price target on the biotechnology companys stock. BTIG Researchs price objective indicates a potential upside of 116.51% from the stocks previous []

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCar

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2021 Results - Earnings Call Transcript

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.67% and -5.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stoc

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inves

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investi

CTMX is trading at cash. They have major collaborations.

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of inves

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2021 Results - Earnings Call Transcript

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -15.38% and -10.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?